McKesson said revenues for the quarter ended June 30, 2025 increased 23% compared to the same prior year period, while diluted earnings per common share attributable to the company decreased to $6.25 from $7.00.

1. 01

   McKesson said revenues for the quarter ended June 30, 2025 increased 23% compared to the same prior year period, while diluted earnings per common share attributable to the company decreased to $6.25 from $7.00.

2. 02

   The company included a provision for bad debts of $189 million in SDG&A for the quarter related to the bankruptcy of customer Rite Aid and cited it as a factor in the decrease in U.S. Pharmaceutical segment operating profit.

3. 03

   McKesson acquired a 80% interest in PRISM Vision for $874 million in cash and a 70% interest in Core Ventures for $2.5 billion in cash, and reflected net cash paid for acquisitions of $3.4 billion in investing activities.

4. 04

   The company said it used $918 million of cash in operating activities for the quarter and used senior unsecured notes issued on May 30, consisting of 3 series (net proceeds of $2.0 billion), to fund the Core Ventures acquisition.

Key figures

Quarter ended June 30, 2025

Revenue

$97.8B

Operating income

$1.0B

Net income

$784M

EPS

$6.25

Gross profit

$3.3B

Operating cash flow

−$918M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.